Cell Therapy News

The FDA placed a clinical hold on a clinical program designed to investigate a chimeric antigen receptor T-cell therapy for treatment of relapsed or refractory multiple myeloma following a patient death.

Nearly 7,000 abstracts had been submitted for presentation at this year’s ASCO Annual Meeting.

Seattle Children’s Hospital has paused the phase 1 PLAT-08 trial of SC-DARIC33 after one patient treated with the investigational chimeric antigen receptor T-cell therapy died.

CHICAGO — Seventy-six percent of adults with relapsed or refractory B-cell acute lymphoblastic leukemia achieved complete response to treatment with obecabtagene autoleucel, interim results of the pivotal phase 2 FELIX trial showed.

Two teenagers with T-cell acute lymphoblastic leukemia achieved complete molecular remission after receiving a donor-based investigational chimeric antigen receptor T-cell therapy, phase 1 study results showed.

CHICAGO — Healio | HemOnc Today gathered the best, brightest and boldest in oncology for its second annual Disruptive Innovators Awards.

CHICAGO — Lisocabtagene maraleucel significantly improved complete remission rates among adults with relapsed or refractory chronic lymphocytic leukemia, results from the pivotal phase 2 TRANSCEND CLL 004 trial showed.

CHICAGO — Ciltacabtagene autoleucel significantly extended PFS compared with standard therapy for adults with relapsed and lenalidomide-refractory multiple myeloma, results from the randomized phase 3 CARTITUDE-4 study showed.

CHICAGO — Second-line therapy with axicabtagene ciloleucel conferred a significant increase in OS compared with the current standard of care among adults with relapsed or refractory large B-cell lymphoma, results of the randomized phase 3 ZUMA-7 study showed.

An investigational chimeric antigen receptor T-cell therapy demonstrated successful expansion and antitumor targeting among younger patients with advanced acute myeloid leukemia, results of the phase 1 PLAT-08 trial showed.